Ascidian
Biotech

Ascidian, Lilly ink RNA exon editing pact worth up to $1.9B

Ascidian and Lilly signed a collaboration worth up to $1.9 billion to develop RNA exon editing therapeutics for genetic kidney diseases.
Will Maddox Jun 3, 2026 7:00am
money time

Anti-aging biotech NewLimit nabs $435M to rejuvenate old cells

Jun 2, 2026 1:00pm
Entry Japan with Clarity Execute with Confidence

PATH-Solution

Brought to you by Alfresa Holdings Corporation
Roche

Roche oral SERD's 1st-line miss spurs new adjuvant trial

Jun 2, 2026 12:45pm
more expensive

Regeneron pays $37M, adds $2B in biobucks to expand CytomX pact

Jun 3, 2026 9:48am
ASCO
Favicon Fierce Pharma

At ASCO, China biotech industry cements its coming of age

Jun 3, 2026 8:50am
More News

Travere scales Everest with $1.1B deal for BTK inhibitor

Jun 2, 2026 10:30am

Fierce Biotech Fundraising Tracker '26: NewLimit, Accro & more

Jun 2, 2026 10:00am

ASCO: Cardiff posts updated colorectal data before pivotal push

Jun 2, 2026 9:06am

Fulcrum scraps SCD plan as FDA takes hard line on safety risks

Jun 2, 2026 8:46am